ArticleCurrent oncology (Toronto, Ont.)2014

Anticancer activity of combination targeted therapy using cetuximab plus vemurafenib for refractory BRAF (V600E)-mutant metastatic colorectal carcinoma.

K Connolly et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.